Seeking Alpha Portfolio App for iPad
Dividends & Income
View as an RSS Feed
Why You Should Be Interested In Northwest Biotherapeutics And ImmunoCellular Therapeutics
I enjoyed your report in April on NWBO & IMUC.
I was looking through the IMUC PR last week & there appeared to be a few discrepancies. i was wondering if you noticed them too?
It stated overall survival of 50% of the 16 patients in the Phase I trial after 48 months. This is inconsistent with the medial overall survival rate of 38.4 months as stated in the Jan 23, 2012 PR.
I also notice that median Progression Free Survival time has decreased when comparing different PR from 19 to under 17 months.
The PR claims progression free (
) for 48-66 months for 38% of the Phase I trial patients. HOWEVER, the Phase I commenced in May 2007 (in the the 10-Q) the duration between May 2007 and June 2012 is 62 months. Something’s wrong somewhere. Either this press release was inaccurate or the past Q was inaccurate. In order for the patients to have reached 66 months in June 2012 they would have needed to start receiving treatment in Jan 2007 but it was first announced that the treatment had started in August 2007.
Jun 8 05:20 AM
Link to Comment
The Opinion Leaders
Xignite quote data
© 2013 Seeking Alpha